Ruan, Jia

Publications

Sort by

Co-Author Network

selected publications

T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood advances. 2020 Academic Article GET IT
Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma. Hematology/oncology clinics of North America. 2020 Review GET IT
Biomarker-driven management strategies for peripheral T cell lymphoma. Journal of hematology & oncology. 2020 Review GET IT
Times cited: 1
An update on options of therapy for aggressive mantle cell lymphoma. Leukemia & lymphoma. 2020 Review GET IT
Molecular profiling and management of mantle cell lymphoma. Hematology. American Society of Hematology. Education Program. 2019 Academic Article GET IT
Times cited: 2
IMiDs New and Old. Current hematologic malignancy reports. 2019 Review GET IT
Times cited: 8
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood. 2019 Academic Article GET IT
Times cited: 19
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leukemia & lymphoma. 2019 Academic Article GET IT
Times cited: 8
Monoclonal plasma cell infiltrates in the setting of cutaneous follicular helper T cell lymphoproliferative disorders. Annals of diagnostic pathology. 2019 Academic Article GET IT
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2019 Academic Article GET IT
Times cited: 26
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 22
Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation. Annals of hematology. 2019 Academic Article GET IT
Times cited: 1
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018 Academic Article GET IT
Times cited: 35
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 10
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis. Blood advances. 2018 Review GET IT
Times cited: 5
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2018 Academic Article GET IT
Times cited: 17
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 38
The potential for chemotherapy-free strategies in mantle cell lymphoma. Blood. 2017 Review GET IT
Times cited: 7
Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma. Leukemia & lymphoma. 2017 Letter GET IT
Times cited: 2
Outcome of Allogeneic and Autologous Hematopoietic Cell Transplantation for High-Risk Peripheral T Cell Lymphomas: A Retrospective Analysis From a Chinese Center. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 4
Primary Cutaneous Follicular Helper T-Cell Lymphoma: A Case Series and Review of the Literature. The American Journal of dermatopathology. 2017 Academic Article GET IT
Times cited: 6
Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nature communications. 2017 Academic Article GET IT
Times cited: 2
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nature communications. 2017 Academic Article GET IT
Times cited: 46
Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways. Oncology (Williston Park, N.Y.). 2016 Review GET IT
Times cited: 1
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clinical epigenetics. 2016 Academic Article GET IT
Times cited: 19
Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy. Current hematologic malignancy reports. 2016 Review GET IT
Times cited: 6
Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 4
Lenalidomide plus Rituximab for Mantle-Cell Lymphoma. The New England journal of medicine. 2016 Letter GET IT
Times cited: 3
Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 Conference Paper GET IT
Times cited: 118
Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2015 Academic Article GET IT
Times cited: 7
Hepatosplenic T-Cell Lymphoma Mimicking Acute Myeloid Leukemia. Clinical lymphoma, myeloma & leukemia. 2015 Academic Article GET IT
Times cited: 5
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 142
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 12
Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 11
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 7
Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. Clinical lymphoma, myeloma & leukemia. 2013 Academic Article GET IT
Times cited: 10
Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer research. 2013 Academic Article GET IT
Times cited: 34
Analysis of prognostic factors for survival in 75 Chinese patients with peripheral T-cell lymphoma. Leukemia & lymphoma. 2013 Letter GET IT
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 2013 Academic Article GET IT
Times cited: 54
EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia. PloS one. 2013 Academic Article GET IT
Times cited: 45
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 22
Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. American journal of hematology. 2012 Letter GET IT
Times cited: 29
Antiangiogenic therapies in non-Hodgkin's lymphoma. Current cancer drug targets. 2011 Review GET IT
Times cited: 11
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 251
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010 Academic Article GET IT
Times cited: 45
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010 Academic Article GET IT
Times cited: 47
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clinical lymphoma, myeloma & leukemia. 2010 Academic Article GET IT
Times cited: 36
Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 105
Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. International journal of hematology. 2009 Academic Article GET IT
Times cited: 74
Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology (Williston Park, N.Y.). 2009 Review GET IT
Times cited: 16
Targeting angiogenesis: a novel, rational therapeutic approach for non-Hodgkin lymphoma. Leukemia & lymphoma. 2009 Comment GET IT
Times cited: 7
Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 246
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Review GET IT
Times cited: 82
New monoclonal antibodies for non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 5
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008 Academic Article GET IT
Times cited: 49
Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Seminars in hematology. 2008 Academic Article GET IT
Times cited: 16
Influence of mitochondrial enzyme deficiency on adult neurogenesis in mouse models of neurodegenerative diseases. Neuroscience. 2008 Academic Article GET IT
Times cited: 49
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 61
Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leukemia & lymphoma. 2008 Academic Article GET IT
Times cited: 31
Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 64
Mantle cell lymphoma: current concept in biology and treatment. Cancer treatment and research. 2006 Review GET IT
Times cited: 5
New developments in immunotherapy for non-Hodgkin's lymphoma. Current oncology reports. 2005 Review GET IT
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005 Academic Article GET IT
Times cited: 207
Peptide methionine sulfoxide reductase from Escherichia coli and Mycobacterium tuberculosis protects bacteria against oxidative damage from reactive nitrogen intermediates. Proceedings of the National Academy of Sciences of the United States of America. 2001 Academic Article GET IT
Times cited: 164
noxR3, a novel gene from Mycobacterium tuberculosis, protects Salmonella typhimurium from nitrosative and oxidative stress. Infection and immunity. 1999 Academic Article GET IT
Times cited: 50
A novel antioxidant gene from Mycobacterium tuberculosis. The Journal of experimental medicine. 1997 Academic Article GET IT
Times cited: 88
Evaluation of bacterial survival and phagocyte function with a fluorescence-based microplate assay. Infection and immunity. 1997 Academic Article GET IT
Times cited: 93
Inducible nitric oxide synthase requires both the canonical calmodulin-binding domain and additional sequences in order to bind calmodulin and produce nitric oxide in the absence of free Ca2+. The Journal of biological chemistry. 1996 Academic Article GET IT
Times cited: 87

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Longitudinal functional genomics in mantle cell lymphoma therapy and drug resistance awarded by Leukemia & Lymphoma Society, Inc. Co-Investigator 2018 - 2022

more ...

less ...

Background

education and training

M.D., Weill Cornell Medical College, Cornell University 1999
Ph.D., Weill Cornell Graduate School of Medical Sciences 1998
B.A., Washington University 1992

Contact

full name

Jia Ruan

primary email

jruan@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Jia Ruan Associate Professor of Clinical Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage